Management of IgE-Mediated Food Allergies

Introduction to Xolair Therapy

The National Institute of Allergy and Infectious Diseases (NIAID)-sponsored expert panel and the American Academy of Allergy, Asthma, and Immunology strongly recommend that individuals with documented IgE-mediated food allergies should avoid ingesting their specific allergen or allergens, as the cornerstone of food allergy management 1

The medical necessity criteria for continued Xolair therapy in IgE-mediated food allergies require three specific elements, including age requirement, clinical response, and continued food avoidance, with documentation of a food-allergen avoidance diet being essential for optimal safety and efficacy, as recommended by the American Academy of Allergy, Asthma, and Immunology 1

The American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force recommends administration of Xolair in a healthcare setting with 2-hour observation for the first 3 doses, epinephrine prescription, and patient education regarding anaphylaxis signs and symptoms for patients with IgE-mediated food allergies 2
Patients receiving Xolair therapy should be monitored for treatment response at scheduled follow-up visits, with repeat skin testing after 6 months to assess effectiveness, and should continue food allergen avoidance measures, maintain epinephrine availability, and document any accidental exposures and reactions 2

Xolair therapy may reduce the risk of anaphylaxis from accidental food exposure and improve quality of life by reducing anxiety related to accidental exposures, but also carries a potential risk of anaphylaxis from the therapy itself (0.2% risk) 2
The proposed dose of 375mg every 2 weeks for Xolair therapy aligns with dosing guidelines based on weight and total IgE levels, with a planned observation period of 2 hours for the first 3 doses following safety recommendations 2

The therapy may not achieve optimal outcomes for reducing morbidity and mortality risks without documentation of continued food allergen avoidance, emphasizing the importance of continued allergen avoidance for optimal safety and efficacy of Xolair therapy, as stated in guidelines from the American Academy of Allergy, Asthma, and Immunology 1